CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment

Title:CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment

Volume: 23 Issue: 12

Author(s): Siddhant Tripathi, Yashika Sharma, Rajesh Rane and Dileep Kumar*

Affiliation:

• Department of Pharm Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune Maharashtra 411038, India

Abstract: In defiance of the vast amount of information regarding Alzheimer's disease (AD) that has been learned over the past thirty years, progress toward developing an effective therapy has been difficult. A neurological ailment that progresses and cannot be reversed is Alzheimer's disease, which shows neurofibrillary tangles, beta-amyloid plaque, and a lack of cognitive processes that is created by tau protein clumps with hyperphosphorylation that finally advances to neuronal damage without a recognized treatment, which has stimulated research into new therapeutic strategies. The protein CAS9 is linked to CRISPR, which is a clustered Regularly Interspaced Short Palindromic Repeat that inactivates or corrects a gene by recognizing a gene sequence that produces a doublestranded break has enchanted a whole amount of interest towards its potency to cure gene sequences in AD. The novel CRISPR-Cas9 applications for developing in vitro and in vivo models to the benefit of AD investigation and therapies are thoroughly analyzed in this work. The discussion will also touch on the creation of delivery methods, which is a significant obstacle to the therapeutic use of CRISPR/Cas9 technology. By concentrating on specific genes, such as those that are significant early- onset AD risk factors and late-onset AD risk factors, like the apolipoprotein E4 (APOE4) gene, this study aims to evaluate the potential application of CRISPR/Cas9 as a possible treatment for AD.

Cite this article as:

Tripathi Siddhant, Sharma Yashika, Rane Rajesh and Kumar Dileep*, CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment, CNS & Neurological Disorders - Drug Targets 2024; 23 (12) . https://dx.doi.org/10.2174/0118715273283786240408034408